Invivyd Says Study Shows VYD2311 Well Tolerated as COVID-19 Drug Candidate

MT Newswires Live06-26

Invivyd (IVVD) said Thursday its phase 1/2 clinical data for VYD2311, a monoclonal antibody candidate to prevent and treat COVID-19, was well tolerated with all adverse events deemed unrelated or classified as mild to moderate in severity.

After six months at the end of the study, serum concentrations of VYD2311 remained high and were observed to be substantially greater than that of Invivyd's first-generation monoclonal antibody, pemivibart, the company said.

Half-life estimates for VYD2311 ranged from 61 days to 76 days as compared with pemivibart estimated half-life of 49 days, potentially providing longer protection and making it more durable, Invivyd said.

The company further said it plans to discuss approval pathways for VYD2311 and follow-on COVID-19 monoclonal antibodies with the US Food and Drug Administration early in Q3.

Invivyd's shares were up more than 3% in recent premarket activity.

Price: 0.73, Change: +0.026, Percent Change: +3.65

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2546787911?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-26 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546787911","market":"fut","top_or_hot":-1,"title":"Invivyd Says Study Shows VYD2311 Well Tolerated as COVID-19 Drug Candidate","media":"MT Newswires Live","content":"<html><body><p> Invivyd (IVVD) said Thursday its phase 1/2 clinical data for VYD2311, a monoclonal antibody candidate to prevent and treat COVID-19, was well tolerated with all adverse events deemed unrelated or classified as mild to moderate in severity.</p><p>After six months at the end of the study, serum concentrations of VYD2311 remained high and were observed to be substantially greater than that of Invivyd's first-generation monoclonal antibody, pemivibart, the company said.</p><p>Half-life estimates for VYD2311 ranged from 61 days to 76 days as compared with pemivibart estimated half-life of 49 days, potentially providing longer protection and making it more durable, Invivyd said.</p><p>The company further said it plans to discuss approval pathways for VYD2311 and follow-on COVID-19 monoclonal antibodies with the US Food and Drug Administration early in Q3.</p><p>Invivyd's shares were up more than 3% in recent premarket activity.</p><p>Price: 0.73, Change: +0.026, Percent Change: +3.65</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Invivyd Says Study Shows VYD2311 Well Tolerated as COVID-19 Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvivyd Says Study Shows VYD2311 Well Tolerated as COVID-19 Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-26 19:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Invivyd (IVVD) said Thursday its phase 1/2 clinical data for VYD2311, a monoclonal antibody candidate to prevent and treat COVID-19, was well tolerated with all adverse events deemed unrelated or classified as mild to moderate in severity.</p><p>After six months at the end of the study, serum concentrations of VYD2311 remained high and were observed to be substantially greater than that of Invivyd's first-generation monoclonal antibody, pemivibart, the company said.</p><p>Half-life estimates for VYD2311 ranged from 61 days to 76 days as compared with pemivibart estimated half-life of 49 days, potentially providing longer protection and making it more durable, Invivyd said.</p><p>The company further said it plans to discuss approval pathways for VYD2311 and follow-on COVID-19 monoclonal antibodies with the US Food and Drug Administration early in Q3.</p><p>Invivyd's shares were up more than 3% in recent premarket activity.</p><p>Price: 0.73, Change: +0.026, Percent Change: +3.65</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4551","symbol_name":"寇图资本持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2546787911","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546787911","pubTimestamp":1750938347,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Invivyd  said Thursday its phase 1/2 clinical data for VYD2311, a monoclonal antibody candidate to prevent and treat COVID-19, was well tolerated with all adverse events deemed unrelated or classified as mild to moderate in severity.After six months at the end of the study, serum concentrations of VYD2311 remained high and were observed to be substantially greater than that of Invivyd's first-generation monoclonal antibody, pemivibart, the company said.Half-life estimates for VYD2311 ranged from 61 days to 76 days as compared with pemivibart estimated half-life of 49 days, potentially providing longer protection and making it more durable, Invivyd said.The company further said it plans to discuss approval pathways for VYD2311 and follow-on COVID-19 monoclonal antibodies with the US Food and Drug Administration early in Q3.Invivyd's shares were up more than 3% in recent premarket activity.Price: 0.73, Change: +0.026, Percent Change: +3.65","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4551":"寇图资本持仓","BK4539":"次新股","BK4588":"碎股","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","IVVD":"Invivyd, Inc.","BNTX":"BioNTech SE","BK4139":"生物科技"},"translate_title":"Invivyd表示研究显示VYD2311作为COVID-19候选药物耐受性良好","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1,"IVVD":0.9},"content_text":"Invivyd (IVVD) said Thursday its phase 1/2 clinical data for VYD2311, a monoclonal antibody candidate to prevent and treat COVID-19, was well tolerated with all adverse events deemed unrelated or classified as mild to moderate in severity.After six months at the end of the study, serum concentrations of VYD2311 remained high and were observed to be substantially greater than that of Invivyd's first-generation monoclonal antibody, pemivibart, the company said.Half-life estimates for VYD2311 ranged from 61 days to 76 days as compared with pemivibart estimated half-life of 49 days, potentially providing longer protection and making it more durable, Invivyd said.The company further said it plans to discuss approval pathways for VYD2311 and follow-on COVID-19 monoclonal antibodies with the US Food and Drug Administration early in Q3.Invivyd's shares were up more than 3% in recent premarket activity.Price: 0.73, Change: +0.026, Percent Change: +3.65","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2546787911","isCrawlerRequest":true}